William Goodmen - STAAR Surgical Vice President - Global Human Resources
| STAA Stock | USD 48.19 1.64 3.52% |
President
Mr. William Walter Goodmen serves as Vice President Global Human Resources of STAAR Surgical Company. Mr. Goodmen joined STAAR in August 2010. Prior to joining STAAR, he served as Vice President, Business Development for Neovia Integrated Insurance Services, a healthcare brokerage firm, from 2009 to 2010. His prior experience also includes seven years at THQ, Inc., a developer of interactive entertainment software where he served as Executive Vice President of Human Resources and Administration from 2002 to 2009. During this time period, he was responsible for all Human Resources and general administrative functions worldwide. Additional experience includes senior management positions in Human Resources at Liberty Livewire and in executive search with Spencer Stuart. He began his human resources career at Atlantic Richfield Co., a Fortune 500 energy company, where he spent 18 years
| Age | 59 |
| Address | 25651 Atlantic Ocean Drive, Lake Forest, CA, United States, 92630 |
| Phone | 626 303 7902 |
| Web | https://www.staar.com |
STAAR Surgical Management Efficiency
The company has return on total asset (ROA) of 0.0409 % which means that it generated a profit of $0.0409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0591 %, meaning that it created $0.0591 on every $100 dollars invested by stockholders. STAAR Surgical's management efficiency ratios could be used to measure how well STAAR Surgical manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.08. The current year's Return On Capital Employed is expected to grow to 0.12. At present, STAAR Surgical's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 129.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 1.8 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Steven Jackson | National Research Corp | 42 | |
| Jeffrey Cunningham | HealthStream | 57 | |
| William Otten | HealthEquity | 52 | |
| Scott McQuigg | HealthStream | 50 | |
| Mollie Condra | HealthStream | N/A | |
| Michael Collier | HealthStream | 48 | |
| Jeffery Doster | HealthStream | 51 | |
| Edward Pearson | HealthStream | 61 | |
| Frode Jensen | HealthEquity | 64 | |
| Michael Sousa | HealthStream | 55 | |
| Trisha Coady | HealthStream | 48 | |
| Jonathan Maack | Definitive Healthcare Corp | 45 | |
| Jonathan Soldan | HealthEquity | 32 | |
| Kevin Karas | National Research Corp | 60 | |
| Delano Ladd | HealthEquity | 43 | |
| Angelique Hill | HealthEquity | 55 | |
| Thomas Schultz | HealthStream | 49 | |
| Edward Bloomberg | HealthEquity | 41 | |
| Larry Trittschuh | HealthEquity | 52 | |
| Ashley Dreier | HealthEquity | 44 | |
| Gary Robinson | HealthEquity | 55 | |
Management Performance
| Return On Equity | 0.0591 | ||||
| Return On Asset | 0.0409 |
STAAR Surgical Leadership Team
Elected by the shareholders, the STAAR Surgical's board of directors comprises two types of representatives: STAAR Surgical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STAAR. The board's role is to monitor STAAR Surgical's management team and ensure that shareholders' interests are well served. STAAR Surgical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STAAR Surgical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Brown, CFO and VP | ||
| HansMartin Blickensdoerfer, President International Commercial Operations | ||
| Surindra Mann, Vice President - Global Financial Planning and Analysis | ||
| Denise McEachern, Global Head of Regulatory Affairs and Quality Assurance | ||
| Douglas Sherk, IR Contact Officer | ||
| William Wall, Director | ||
| Louis Silverman, Director | ||
| James Francese, VP of Global Marketing | ||
| Richard Meier, Independent Director | ||
| Scott MD, Chief Officer | ||
| Graydon Hansen, Senior Vice President - Global Operations | ||
| Magda Michna, Regulatory Clinical | ||
| John Santos, Vice President - Global Quality Assurance, Regulatory and Clinical Affairs | ||
| Mark Logan, Independent Chairman of the Board | ||
| Steven Roush, Director | ||
| Stephen Farrell, Director | ||
| Brian Moore, IR Contact Officer | ||
| Warren Foust, Chief Officer | ||
| Thomas Frinzi, CEO President | ||
| Samuel Gesten, Vice President General Counsel, Corporate Compliance Officer and Secretary | ||
| Deborah Andrews, Chief Accounting Officer and VP | ||
| William Goodmen, Vice President - Global Human Resources | ||
| Caren Mason, CEO and President Director and Chairman of Quality and Regulatory Committee | ||
| Scott Barnes, Chief Medical Officer | ||
| Joanne Egamino, Global Operations | ||
| Donald Fagen, Vice President - North American Sales | ||
| Patrick Williams, Chief Officer | ||
| Robert Studholme, Senior Operations | ||
| John Moore, Independent Director | ||
| Doug Sherk, IR Contact Officer | ||
| Jon Hayashida, Vice President of Global Clinical and Medical Affairs | ||
| Keith Holliday, Vice President - Research & Development | ||
| Paul Hambrick, Vice President - Global Operations | ||
| Philippe Subrin, Vice President - Switzerland Operations |
STAAR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is STAAR Surgical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0591 | ||||
| Return On Asset | 0.0409 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 2.09 B | ||||
| Shares Outstanding | 48.87 M | ||||
| Shares Owned By Insiders | 0.78 % | ||||
| Shares Owned By Institutions | 99.22 % | ||||
| Number Of Shares Shorted | 5.27 M | ||||
| Price To Earning | 460.83 X |
STAAR Surgical Investors Sentiment
The influence of STAAR Surgical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in STAAR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to STAAR Surgical's public news can be used to forecast risks associated with an investment in STAAR. The trend in average sentiment can be used to explain how an investor holding STAAR can time the market purely based on public headlines and social activities around STAAR Surgical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
STAAR Surgical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for STAAR Surgical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average STAAR Surgical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on STAAR Surgical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards STAAR Surgical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, STAAR Surgical's short interest history, or implied volatility extrapolated from STAAR Surgical options trading.
Currently Active Assets on Macroaxis
When determining whether STAAR Surgical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of STAAR Surgical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Staar Surgical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Staar Surgical Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in STAAR Surgical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade STAAR Stock refer to our How to Trade STAAR Stock guide.Note that the STAAR Surgical information on this page should be used as a complementary analysis to other STAAR Surgical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for STAAR Stock analysis
When running STAAR Surgical's price analysis, check to measure STAAR Surgical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy STAAR Surgical is operating at the current time. Most of STAAR Surgical's value examination focuses on studying past and present price action to predict the probability of STAAR Surgical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move STAAR Surgical's price. Additionally, you may evaluate how the addition of STAAR Surgical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is STAAR Surgical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of STAAR Surgical. If investors know STAAR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about STAAR Surgical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.221 | Earnings Share 0.43 | Revenue Per Share 6.645 | Quarterly Revenue Growth 0.191 | Return On Assets 0.0409 |
The market value of STAAR Surgical is measured differently than its book value, which is the value of STAAR that is recorded on the company's balance sheet. Investors also form their own opinion of STAAR Surgical's value that differs from its market value or its book value, called intrinsic value, which is STAAR Surgical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because STAAR Surgical's market value can be influenced by many factors that don't directly affect STAAR Surgical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between STAAR Surgical's value and its price as these two are different measures arrived at by different means. Investors typically determine if STAAR Surgical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, STAAR Surgical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.